InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-27.7%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Pellegrini Niamh Louise, Executive. Insider active across 2 companies, notably NEVRO CORP. Cumulatively, 13 disclosures have been logged. History available since 6 August 2021. The latest transaction was filed on 15 June 2023 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations13 total
8,400 shares0FORM 4SEC:0001628280-23-022323:0
1,143 shares@ US$26.452.0% of flowCommon StockSEC:0001610717-23-000082:0
39,282 shares0Common StockSEC:0001567619-23-004745:0
1,979 shares@ US$33.994.4% of flowCommon StockSEC:0001567619-23-004533:0
4,718 shares@ US$31.449.7% of flowCommon StockSEC:0001567619-23-004208:0
4,365 shares@ US$47.1113.9% of flowCommon StockSEC:0001567619-22-015195:0
8,400 shares0Common StockSEC:0000950103-22-010953:0
2,031 shares@ US$71.2712.8% of flowCommon StockSEC:0001567619-22-006438:0
26,069 shares0Common StockSEC:0001567619-22-006143:0
4,172 shares0Common StockSEC:0000950103-21-012267:0
4,172 shares0Common StockSEC:0000950103-21-012267
4,366 shares@ US$119.7343.6% of flowCommon StockSEC:0001567619-21-014908:0
4,366 shares@ US$119.7330.6% of flowCommon StockSEC:0001567619-21-014908
13 of 13 declarations
About Pellegrini Niamh Louise
Niamh Louise Pellegrini is the Chief Commercial Officer and Director at NEVRO CORP and Acutus Medical, Inc. She oversees business and product development strategies for these medical technology companies. Niamh is committed to improving patient outcomes through innovative solutions.
